Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by Stifel Financial Corp

Stifel Financial Corp cut its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 75.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,944 shares of the company’s stock after selling 301,538 shares during the quarter. Stifel Financial Corp owned approximately 0.11% of Aquestive Therapeutics worth $478,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Victory Capital Management Inc. acquired a new stake in Aquestive Therapeutics during the 2nd quarter worth $27,000. nVerses Capital LLC acquired a new position in Aquestive Therapeutics during the third quarter worth about $28,000. The Manufacturers Life Insurance Company purchased a new stake in Aquestive Therapeutics during the 2nd quarter valued at about $76,000. Financial Advocates Investment Management raised its holdings in Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after acquiring an additional 14,000 shares during the last quarter. Finally, Harvey Capital Management Inc. purchased a new position in Aquestive Therapeutics in the 3rd quarter worth approximately $88,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AQST has been the subject of a number of analyst reports. JMP Securities restated a “market outperform” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Leerink Partners upped their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Finally, Cantor Fitzgerald initiated coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $11.00.

Aquestive Therapeutics Stock Performance

Shares of Aquestive Therapeutics stock opened at $3.52 on Friday. Aquestive Therapeutics, Inc. has a fifty-two week low of $1.95 and a fifty-two week high of $6.23. The firm has a market capitalization of $320.95 million, a price-to-earnings ratio of -7.82 and a beta of 2.62. The stock has a 50 day moving average of $4.61 and a 200 day moving average of $4.09.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same period in the previous year, the company posted ($0.03) EPS. Analysts forecast that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.